

LSP Advisory viert notering van LSP Life Sciences Fund N.V. op NYSE Euronext Amsterdam.

AMSTERDAM, THE NETHERLANDS, May 4th 2011

LSP Advisory B.V.

LSP Advisory B.V. behoort tot de LSP groep, één van Europa's grootste en meest gerespecteerde beleggingsfirma's op het gebied van gezondheidszorg en biotechnologie, viert vandaag de notering van LSP Life Sciences Fund N.V. op NYSE Euronext Amsterdam. Gezien de diversiteit en complexiteit van deze sector, is gespecialiseerde kennis noodzakelijk om veelbelovende beleggingskansen te kunnen identificeren. Als specialist in het beleggen in het life sciences industrie met meer dan twintig jaar ervaring, heeft LSP haar expertise bewezen wat betreft het vinden en koesteren van de meest succesvolle bedrijven. LSP heeft een sterke track record ontwikkeld als verschafter van zowel durfkapitaal als private equity.



About the Fund

The Fund is an open-end Dutch public company (N.V.) with the status of investment company with variable capital and is an exempt investment institution for Dutch tax purposes. The Fund will be managed by LSP Advisory B.V. As from 27 April 2011, the shares in the Fund (ISIN: NL0009756394; NYSE Euronext: LSP) will be traded through the Euronext Fund Service system for open-end investment funds. The issuance price is EUR 100 per share. The prospectus of the Fund and further Fund-related information will be available as from today at the offices of LSP Advisory BV and can be downloaded from the website of the Fund: www.lsplifesciencesfund.com

About LSP

With a history going back to the late eighties, LSP has grown into one of Europe's most experienced and largest specialized biotechnology investment firms. With offices in Amsterdam, Munich and Boston and a dedicated team of seasoned investment professionals, the firm has built a superior investment track record over a period exceeding 20 years. Key to the firm's success has been its one sector specialization and – hence – its deep and fundamental understanding of the biotechnology sector. Supported by an expert and advisory network of clinicians, scientists, pharma and biotech executives, regulatory policy makers and academic thought leaders, the firm has built a unique knowledge base that allows it to find and assess investment opportunities that fall outside the scope and capabilities of more generalist investors. For more information on LSP please visit www.lspvc.com

For further enquiries

Mark Wegter
Joep Muijers PhD

t: +31 20 664 55 00
@: info@lspifesciencesfund.com